Press "Enter" to skip to content

Top 5 Need To Know Cancer Breakthrough Facts


[Music]

[Music] search for a cancer cure is ongoing but

search for a cancer cure is ongoing but

search for a cancer cure is ongoing but recent research may have given us an

recent research may have given us an

recent research may have given us an edge in the fight welcome to

edge in the fight welcome to

edge in the fight welcome to watchmojo.com will write down news

watchmojo.com will write down news

watchmojo.com will write down news stories that might be on your radar in

stories that might be on your radar in

stories that might be on your radar in this installment we’re counting down 5

this installment we’re counting down 5

this installment we’re counting down 5 need-to-know facts about the ongoing

need-to-know facts about the ongoing

need-to-know facts about the ongoing effort to fight cancer and the T cell

effort to fight cancer and the T cell

effort to fight cancer and the T cell breakthrough number 5 what is T cell

breakthrough number 5 what is T cell

breakthrough number 5 what is T cell cancer therapy research into T cell

cancer therapy research into T cell

cancer therapy research into T cell therapy a form of immunotherapy has been

therapy a form of immunotherapy has been

therapy a form of immunotherapy has been labeled a revolution in humankind’s

labeled a revolution in humankind’s

labeled a revolution in humankind’s battle against cancer well the doctor is

battle against cancer well the doctor is

battle against cancer well the doctor is in with a revolutionary technique that

in with a revolutionary technique that

in with a revolutionary technique that might be their newest tool in the fight

might be their newest tool in the fight

might be their newest tool in the fight against cancer some experts have even

against cancer some experts have even

against cancer some experts have even called immunotherapy the fifth pillar of

called immunotherapy the fifth pillar of

called immunotherapy the fifth pillar of cancer treatment alongside surgery

cancer treatment alongside surgery

cancer treatment alongside surgery chemotherapy radiation and targeted

chemotherapy radiation and targeted

chemotherapy radiation and targeted therapies a new approach which is yet to

therapies a new approach which is yet to

therapies a new approach which is yet to be widely tested the experimental

be widely tested the experimental

be widely tested the experimental treatment works by equipping the body

treatment works by equipping the body

treatment works by equipping the body with modified T cells the type of white

with modified T cells the type of white

with modified T cells the type of white blood cell which can systematically

blood cell which can systematically

blood cell which can systematically attack weak points on a cancerous tumor

attack weak points on a cancerous tumor

attack weak points on a cancerous tumor those weak points called antigens are

those weak points called antigens are

those weak points called antigens are proteins attached to the surface of

proteins attached to the surface of

proteins attached to the surface of cancerous cells and have been described

cancerous cells and have been described

cancerous cells and have been described as cancers Achilles heel as part of the

as cancers Achilles heel as part of the

as cancers Achilles heel as part of the research cancer growth has been compared

research cancer growth has been compared

research cancer growth has been compared to a tree so called branches spread out

to a tree so called branches spread out

to a tree so called branches spread out from a central trunk complicating a

from a central trunk complicating a

from a central trunk complicating a cancerous mass but T cell therapy

cancerous mass but T cell therapy

cancerous mass but T cell therapy targets the trunk aiming to bring down

targets the trunk aiming to bring down

targets the trunk aiming to bring down the branches in turn to comprehensively

the branches in turn to comprehensively

the branches in turn to comprehensively remove any threat number 4 who is

remove any threat number 4 who is

remove any threat number 4 who is leading the cancer research research has

leading the cancer research research has

leading the cancer research research has been an international effort involving

been an international effort involving

been an international effort involving scientists from the UK US Germany and

scientists from the UK US Germany and

scientists from the UK US Germany and Denmark and largely funded by Cancer

Denmark and largely funded by Cancer

Denmark and largely funded by Cancer Research UK dr. Sergio Quezada of

Research UK dr. Sergio Quezada of

Research UK dr. Sergio Quezada of University College London Cancer

University College London Cancer

University College London Cancer Institute described it as the most

Institute described it as the most

Institute described it as the most amazing collaboration he’d ever worked

amazing collaboration he’d ever worked

amazing collaboration he’d ever worked on and Professor Charles Swanton

on and Professor Charles Swanton

on and Professor Charles Swanton co-author of the study published in

co-author of the study published in

co-author of the study published in science and also of UCL explained how

science and also of UCL explained how

science and also of UCL explained how immunotherapy can take personalized

immunotherapy can take personalized

immunotherapy can take personalized medicine to its absolute limit dr.

medicine to its absolute limit dr.

medicine to its absolute limit dr. Stanley Redell is the one credited for

Stanley Redell is the one credited for

Stanley Redell is the one credited for successful early testing as he made

successful early testing as he made

successful early testing as he made headlines in February 2016 when his

headlines in February 2016 when his

headlines in February 2016 when his experimental treatment at Seattle’s Fred

experimental treatment at Seattle’s Fred

experimental treatment at Seattle’s Fred Hutchinson Cancer Research Center blew

Hutchinson Cancer Research Center blew

Hutchinson Cancer Research Center blew unprecedented results for example a

unprecedented results for example a

unprecedented results for example a small group of 29 patients with

small group of 29 patients with

small group of 29 patients with previously incurable or constantly

previously incurable or constantly

previously incurable or constantly in lymphoblastic leukemia underwent

in lymphoblastic leukemia underwent

in lymphoblastic leukemia underwent Rydell’s immune cell therapy and 93%

Rydell’s immune cell therapy and 93%

Rydell’s immune cell therapy and 93% went into complete remission number

went into complete remission number

went into complete remission number three what would be the potential

three what would be the potential

three what would be the potential treatments doctor Quezada has suggested

treatments doctor Quezada has suggested

treatments doctor Quezada has suggested that recent developments could lead to

that recent developments could lead to

that recent developments could lead to two types of treatment customized

two types of treatment customized

two types of treatment customized vaccines or targeted T cell production a

vaccines or targeted T cell production a

vaccines or targeted T cell production a vaccine designed to tackle each

vaccine designed to tackle each

vaccine designed to tackle each individual cancer would represent the

individual cancer would represent the

individual cancer would represent the ultimate personalized form of therapy

ultimate personalized form of therapy

ultimate personalized form of therapy and could yield exceptionally efficient

and could yield exceptionally efficient

and could yield exceptionally efficient results if we’re able to identify the

results if we’re able to identify the

results if we’re able to identify the trunk of any tumor then there’s

trunk of any tumor then there’s

trunk of any tumor then there’s potential for us to vaccinate against

potential for us to vaccinate against

potential for us to vaccinate against the vast majority the second treatment

the vast majority the second treatment

the vast majority the second treatment involves fishing T cells from a patient

involves fishing T cells from a patient

involves fishing T cells from a patient multiplying them outside of the body and

multiplying them outside of the body and

multiplying them outside of the body and then re injecting them for a stronger

then re injecting them for a stronger

then re injecting them for a stronger more effective attack on cancerous cells

more effective attack on cancerous cells

more effective attack on cancerous cells there are drawbacks to both methods

there are drawbacks to both methods

there are drawbacks to both methods however including speed limitations and

however including speed limitations and

however including speed limitations and high expenses number two what was the

high expenses number two what was the

high expenses number two what was the outcome for patients although the new

outcome for patients although the new

outcome for patients although the new treatments are not likely to be widely

treatments are not likely to be widely

treatments are not likely to be widely used for some time initial tests have

used for some time initial tests have

used for some time initial tests have produced encouraging results that’s a

produced encouraging results that’s a

produced encouraging results that’s a really first attempt to determine how

really first attempt to determine how

really first attempt to determine how how widely applicable we can make this

how widely applicable we can make this

how widely applicable we can make this therapy as well as rudel’s ninety-three

therapy as well as rudel’s ninety-three

therapy as well as rudel’s ninety-three percent success rate the researcher also

percent success rate the researcher also

percent success rate the researcher also saw 65% of 30 participants with

saw 65% of 30 participants with

saw 65% of 30 participants with non-hodgkins lymphoma go into remission

non-hodgkins lymphoma go into remission

non-hodgkins lymphoma go into remission in total Redell has treated around 100

in total Redell has treated around 100

in total Redell has treated around 100 patients with the therapy with mostly

patients with the therapy with mostly

patients with the therapy with mostly favorable outcomes

favorable outcomes

favorable outcomes much of the early testing performed by

much of the early testing performed by

much of the early testing performed by Redell and others has been carried out

Redell and others has been carried out

Redell and others has been carried out on patients for whom all other options

on patients for whom all other options

on patients for whom all other options had failed in some cases people have

had failed in some cases people have

had failed in some cases people have been given months to live before

been given months to live before

been given months to live before undergoing immunotherapy and then

undergoing immunotherapy and then

undergoing immunotherapy and then recovered according to doctor Renier J

recovered according to doctor Renier J

recovered according to doctor Renier J Brenton’s of Memorial sloan-kettering

Brenton’s of Memorial sloan-kettering

Brenton’s of Memorial sloan-kettering cancer center in New York and another

cancer center in New York and another

cancer center in New York and another leading figure in the early trials

leading figure in the early trials

leading figure in the early trials results so far are quote proof of

results so far are quote proof of

results so far are quote proof of principle that we can successfully alter

principle that we can successfully alter

principle that we can successfully alter patients T cells so that they attack

patients T cells so that they attack

patients T cells so that they attack their cancer cells number one what does

their cancer cells number one what does

their cancer cells number one what does this mean for the fight against cancer

this mean for the fight against cancer

this mean for the fight against cancer while this is a significant development

while this is a significant development

while this is a significant development and a potentially crucial step forward

and a potentially crucial step forward

and a potentially crucial step forward it’s important to remember that the T

it’s important to remember that the T

it’s important to remember that the T cell immunotherapy breakthrough is not a

cell immunotherapy breakthrough is not a

cell immunotherapy breakthrough is not a cure for cancer yet it’s too early to

cure for cancer yet it’s too early to

cure for cancer yet it’s too early to fully back the treatment which has so

fully back the treatment which has so

fully back the treatment which has so far produced promising results but on a

far produced promising results but on a

far produced promising results but on a small scale

small scale

small scale Charles Swanson has himself underlined

Charles Swanson has himself underlined

Charles Swanson has himself underlined that the research is still in its infant

that the research is still in its infant

that the research is still in its infant we’re not naive he said we know there’s

we’re not naive he said we know there’s

we’re not naive he said we know there’s a long way to go this is the first step

a long way to go this is the first step

a long way to go this is the first step in an exciting journey

in an exciting journey

in an exciting journey however excitement has naturally bred

however excitement has naturally bred

however excitement has naturally bred hope as doctors looked to t cell

hope as doctors looked to t cell

hope as doctors looked to t cell research to potentially save millions of

research to potentially save millions of

research to potentially save millions of lives every year the work of Swanton

lives every year the work of Swanton

lives every year the work of Swanton Quezada Redell and others could still

Quezada Redell and others could still

Quezada Redell and others could still prove to be a false dawn but recent

prove to be a false dawn but recent

prove to be a false dawn but recent trials are sure to be considered a

trials are sure to be considered a

trials are sure to be considered a landmark moment and clear step in the

landmark moment and clear step in the

landmark moment and clear step in the right direction

right direction

right direction did these backs get you thinking to vote

did these backs get you thinking to vote

did these backs get you thinking to vote for which news story is covered next

for which news story is covered next

for which news story is covered next head over to watchmojo.com slash suggest

head over to watchmojo.com slash suggest

head over to watchmojo.com slash suggest and be sure to hit that subscribe button

and be sure to hit that subscribe button

and be sure to hit that subscribe button for more newsworthy top 10s published

for more newsworthy top 10s published

for more newsworthy top 10s published every week

”

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *